December 23, 2015.
Amgen (Thousand Oaks, CA) has acquired Catherex from Medigene (Munich, Germany) for an upfront payment of $10.5 million.
Medigene will receive about 40 percent of the payments from Amgen, while Catherex shareholders will receive the upfront payment plus milestone payments based on Amgen’s Imlygic, which was approved by FDA in October 2015 for the treatment of advanced, metastatic melanoma. Catherex, located in Philadelphia, PA, was spun off from Medigene in April 2010 with the development of a cancer-killing herpes simplex virus (oHSV).
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.